The panel members that have proposed the recommendations have found clinical utility for several genomic tests to guide clinical decision in women with early stage breast cancer.
The American Society of Clinical Oncology (ASCO) today issued a new clinical practice guideline for women with early-stage invasive breast cancer and known hormone receptor and human epidermal growth factor 2 (HER2) receptor status.
The 13 panel members—with expertise in medical oncology, radiation oncology, community oncology, statistics, and health outcome researchers—conducted a literature review of relevant studies published during the period between 2006 and 2014 that included overall survival and disease-free or recurrence-free survival as the measured outcomes. A cancer survivor on the panel represented the patient perspective. The review narrowed down the search to 50 relevant papers, which included 1 randomized trial and 18 prospective-retrospective studies that evaluated clinical utility of specific biomarkers as a guide for decisions on adjuvant systemic therapy.
Published in the Journal of Clinical Oncology, the guideline looks to answer the following questions:
The following are the primary guideline recommendations:
In a press statement released with the guidelines, Lyndsay N. Harris, MD, co-chair of the ASCO expert panel that developed the guideline said, “In the era of precision medicine, the role of biomarkers in guiding clinical care is greater than in the past. An extensive number of new tests have come out in the last 5-10 years, but not all have sufficient evidence of clinical utility. These latest recommendations truly inform physicians about which tests need to be performed. But this is not all that goes into patient care. Doctors need to continue discussions with patients to develop individualized treatment plans.”
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Read More